Vi­iV's long-act­ing Cabe­nu­va beats out dai­ly oral HIV treat­ments in PhI­II

Vi­iV Health­care had al­ready shown that its long-act­ing in­jectable Cabe­nu­va was just as ef­fec­tive as dai­ly oral treat­ments as well as pre­ferred by pa­tients for its con­ve­nience — now the treat­ment has proven su­pe­ri­or to a dai­ly oral too, ac­cord­ing to an in­ter­im analy­sis of a Phase III study.

GSK’s Vi­iV said Wednes­day that in the LAT­I­TUDE study, Cabe­nu­va demon­strat­ed su­pe­ri­or ef­fi­ca­cy in main­tain­ing vi­ral load sup­pres­sion com­pared to a dai­ly oral ther­a­py when giv­en to pa­tients who have a his­to­ry of chal­lenges ad­her­ing to an­ti­retro­vi­ral treat­ments.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER